#FillTheSeats to save lives this February with Canadian Blood Services – Sportsnet.ca

Help Fill the Seats to save lives this February!

Canadian Blood Services is encouraging new and existing blood donors to help fill up to 6,690 appointments in Calgary and to consider making a Plasma or Steam cell donation. Currently, the need for plasma and steam cell donations is urgent.

Plasma is needed more than four times what is donated in Canada. It could take over 100 plasma donations to help treat one patient for a year. These donations go to patients who need transfusions, as well as to fractionators for manufacturing specialized medicines needed by Canadians with conditions such as bleeding disorders, burns and immunodeficiency. The winter season is typically a challenging time for blood and plasma collections due to winter hazards and weather impacts.

Stem Cell transplants can treat over 80 different diseases and disorders. Each year, hundreds of patients in Canada with cancers and blood diseases need a stem cell transplant to save their life many of whom are facing challenges finding a matching donor. A stem cell transplant replaces the patients unhealthy stem cells with a matching donors healthy stem cells. There are three sources of stem cells used in transplant:

Potential volunteer stem cell donors and expectant moms can also help save lives by donating cord blood.

Blood & Plasma donations are by appointment only. To book yours go to blood.ca, right click on find a location, enter Eau Claire Market and choose Calgary permanent clinic. To learn more about Stem Cell transplants, join the stem cell registry at https://www.blood.ca/en/stemcells.

Originally posted here:
#FillTheSeats to save lives this February with Canadian Blood Services - Sportsnet.ca

ClearPoint Neuro, Inc. Announces Expansion of Pre-Clinical and Translational Development Team to Support Gene and Stem Cell Therapy Partners -…

January 26, 2021 16:05 ET | Source: ClearPoint Neuro, Inc.

IRVINE, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Ernesto Salegio, PhD will join the Company as Vice President, Segment Leader Translational and Pre-Clinical Research as part of ClearPoints Biologics and Drug Delivery team on March 1, 2021. Dr. Salegio brings over 19 years of experience in translational neuroscience with direct pre-clinical central nervous system (CNS) expertise in the delivery of therapeutics to the brain and spinal cord, including over 16 years of gene therapy experience working with adeno-associated viral vectors (AAV).

ClearPoint Neuros Biologics and Drug Delivery team was established in 2020 to provide turn-key medical device innovation, therapy delivery development and clinical services customized for both pharmaceutical and academic partners working on gene and stem cell therapies to the brain. This team also offers comprehensive services to help its partners navigate existing regulatory guidance and stay abreast of anticipated changes to guidance that will inevitably come.

Our current and prospective partners working on gene and stem cell therapies have an enormous unmet need for pre-clinical support, commented Jeremy Stigall, Vice President, Biologics & Drug Delivery Development. Ernestos extensive pre-clinical expertise in the intraparenchymal administration of therapeutics under image-guidance, as well into cerebrospinal fluid (CSF), will allow ClearPoint to add crucial translational consulting services for our biologics partners. When we establish relationships with pharmaceutical partners well before the clinic, ClearPoint products and services can be incorporated throughout the entire development process, delivering consistent, predictable performance, and providing government agencies assurance that the navigation and delivery platform will remain constant from bench-to-bedside. We aim to become their comprehensive medical device partner, allowing them to focus on more traditional pharmaceutical challenges, while ClearPoint delivers state-of-the-art medical device and therapy delivery.

I am thrilled to become a member of the ClearPoint team, commented Dr. Salegio. After spending almost two decades focusing on translational research, image-guided delivery protocols, complex surgical procedures and in the development of CNS therapies, I am delighted to drive the expansion of ClearPoints capabilities. I am eager to leverage their current pre-clinical and clinical portfolio, as well as to their pipeline of innovative tools on the horizon, to provide customized solutions to current and future ClearPoint pharmaceutical partners.

About ClearPoint Neuro

ClearPoint Neuros mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Companys current product portfolio include deep-brain stimulation, laser ablation, biopsy, neuro-aspiration, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint Neuro Navigation System has FDA clearance, is CE-marked, and is installed in over 60 active clinical sites in the United States and the EU. The Companys SmartFlow cannula is being used in partnership or evaluation with 25 individual biologics and drug delivery companies in various stages from preclinical research to late-stage regulatory trials. To date, more than 4,000 cases have been performed and supported by the Companys field-based clinical specialist team which offers support and services for our partners. For more information, please visit http://www.clearpointneuro.com.

Forward-Looking Statements

Statements herein concerning the Companys plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to the impact of COVID-19 and the measures adopted to contain its spread; future revenues from sales of the Companys ClearPoint Neuro Navigation System products; the Companys ability to market, commercialize and achieve broader market acceptance for the Companys ClearPoint Neuro Navigation System products; and estimates regarding the sufficiency of the Companys cash resources. More detailed information on these and additional factors that could affect the Companys actual results are described in the Risk Factors section of the Companys Annual Report on Form 10-K for the year ended December 31, 2019, and the Companys Quarterly Report on Form 10-Q for the three months ended September 30, 2020, both of which have been filed with the Securities and Exchange Commission, and the Companys Annual Report on Form 10-K for the year ended December 31 2020, which the Company intends to file with the Securities and Exchange Commission on or before March 31, 2021.

Continue reading here:
ClearPoint Neuro, Inc. Announces Expansion of Pre-Clinical and Translational Development Team to Support Gene and Stem Cell Therapy Partners -...

Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes…

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND, enabling the company to proceed with initiating a clinical trial for VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell therapy to treat T1D. Vertex plans to initiate a Phase 1/2 clinical trial in the first half of 2021 in patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia.

As we celebrate the 100th anniversary of the discovery of insulin this year, we are excited to bring a first-in-class cell therapy to the clinic with the potential to meaningfully impact people living with T1D, said Bastiano Sanna, Ph.D., Executive Vice President and Chief of Cell and Genetic Therapies at Vertex. We look forward to getting our clinical program underway and testing our unique approach of replacing pancreatic islet cells, which are destroyed in people with type 1 diabetes, with our stem cell-derived fully differentiated insulin-producing pancreatic islet cells.

About VX-880 VX-880, formerly known as STx-02, is an investigational allogeneic human stem cell-derived islet cell therapy that is being evaluated for patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. VX-880 has the potential to restore the bodys ability to regulate glucose levels by restoring pancreatic islet cell function, including insulin production.

The VX-880 clinical trial will involve an infusion of fully differentiated, functional islet cells, as well as the chronic administration of concomitant immunosuppressive therapy, to protect the islet cells from immune rejection.

About the Phase 1/2 Clinical Trial The clinical trial is a Phase 1/2, single-arm, open-label study in subjects who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. This will be a sequential, multi-part clinical trial to evaluate the safety and efficacy of different doses of VX-880. Approximately 17 patients will be enrolled in the clinical trial.

About Type 1 Diabetes T1D results from the autoimmune destruction of insulin-producing islet cells in the pancreas, leading to loss of insulin production and impairment of blood glucose control. The absence of insulin leads to abnormalities in how the body processes nutrients, leading to high blood glucose levels. High blood glucose can lead to diabetic ketoacidosis and over time, to complications such as kidney disease/failure, eye disease (including vision loss), heart disease, stroke, nerve damage and even death. Due to the limitations and complexities of insulin delivery systems, it can be difficult to achieve and maintain balance in glucose control in patients with T1D. Hypoglycemia remains a critical limiting factor in glycemic management, and severe hypoglycemia can cause loss of consciousness, coma, seizures, injury, and can be fatal.

There are currently limited treatment options beyond insulin for the management of T1D.

About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) a rare, life-threatening genetic disease and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of cell and genetic therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 11 consecutive years on Science magazine's Top Employers list and a best place to work for LGBTQ equality by the Human Rights Campaign. For company updates and to learn more about Vertex's history of innovation, visit http://www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements made by Bastiano Sanna, Ph.D., in this press release, statements regarding the development, plans and expectations for our T1D pipeline program, including our plans to initiate a Phase 1/2 clinical trial in people with T1D and expected timeline of our clinical trials, statements regarding patient enrollment and dosing, statements regarding potential clinical trial results and anticipated benefits of VX-880, and our plans to provide further updates on our T1D pipeline program. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that the FDA may not approve our IND, that data from a limited number of patients may not be indicative of final clinical trial results, that data from the company's development programs may not support registration or further development due to safety, efficacy or other reasons, that the COVID-19 pandemic may impact the status or progress of our clinical trials, and other risks listed under the heading Risk Factors in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at http://www.sec.gov and available through the company's website at http://www.vrtx.com. You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

Read more:
Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes...

Cell Therapy Market 2020 Industry Size, Share, Segmentation, Comprehensive Analysis and Forecast by 2025 KSU | The Sentinel Newspaper – KSU | The…

Global Cell Therapy Market 2020 by Company, Type and Application, Forecast to 2025 released at MarketQuest.biz offers widespread assessment and emphasizes fundamental synopsis of the global industry, embracing categorizations, applications, explanations, and manufacturing chain structure. The report discloses the overview of the market and then analyzes the market size (in terms of value and volume) and forecast by type, application/end-user, and region. The report contains a market competitive landscape and company profile between vendors, as well as market price analysis and value chain characteristics. The global Cell Therapy market research report sheds light on the assessment of its diverse segments and main geographies.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

Competitors Analysis:

The competitive landscape offers a corresponding detailed analysis of the major vendors/manufacturers in the global Cell Therapy market. The report examined the key drivers influencing market growth, opportunities, challenges, and the risks faced by key players and the market. It also assesses key emerging trends and their impact on present and future development. This research study assists users to evaluate company shares analysis, emerging product lines, pricing strategies, innovation possibilities, and much more.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketquest.biz/sample-request/26120

The competitive terrain of the market, as per the report, is inclusive of numerous companies such as: Gilead Sciences, Beike Biotechnology, Vericel Corporation, Novartis, JCR Pharmaceuticals, Osiris, Guanhao Biotech, Fujifilm Cellular Dynamics, Vcanbio, Golden Meditech

In market segmentation by types, the report covers: Stem Cell, Non-Stem Cell

In market segmentation by applications, the report covers the following uses: Hospital, Clinic

Regionally, this report focuses on several key regions: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia, Italy, Spain, Benelux, Nordic), Asia (China, Japan, Korea, India, Southeast Asia, Australia and Taiwan), South America (Brazil, Argentina), MENA (Saudi Arabia, UAE, Turkey)

The report also specifies the computed expected CAGR of the market estimated on the basis of the existing and previous records concerning the global Cell Therapy market. Besides, the report covers various tactics to discover the weaknesses, opportunities, risks, and strengths having the potential to impact the global market expansion. The report helps to evaluate and understand the market and its applications on a global level.

Key Deliverables In The Study:

ACCESS FULL REPORT: https://www.marketquest.biz/report/26120/global-cell-therapy-market-2020-by-company-type-and-application-forecast-to-2025

Moreover, the report is assumed as the keeping source for market profitability in the research that is expected to raise the business potentials. In addition, the global Cell Therapy market report provides innovative strategies towards the SWOT study, examination of the industrial development. Also, the report delivers breakdown and data triangulation, consumer needs/customer preference change, research findings, market size estimation, and data source.

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketquest.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact Us Mark Stone Head of Business Development Phone: +1-201-465-4211 Email: sales@marketquest.biz Web: http://www.marketquest.biz

Here is the original post:
Cell Therapy Market 2020 Industry Size, Share, Segmentation, Comprehensive Analysis and Forecast by 2025 KSU | The Sentinel Newspaper - KSU | The...

TScan Moves Toward the Clinic with $100 Million Series C Round – BioSpace

David Southwell, chief executive officer of TScan, pictured above.

T cell company TScan Therapeutics announced it will push two cancer therapies into the clinic this year thanks to a $100 million Series C round, led by an undisclosed U.S.-based, healthcare-focused fund that added new investors BlackRock and RA Capital Management in the process.

The company has now raised over $180 million and continues to rack up partnerships around its T cell receptor (TCR)-based technology, mostly over the past 18 months.

David Southwell, chief executive officer of TScan, told BioSpace the company is poised for an initial public offering sometime in 2021.

TScan is developing off-the-shelf engineered T cell cancer therapies based on TCRs that target tumor antigens identified through genome-wide, high-throughput target identification screening. The company now expects to submit INDs and begin clinical trials for its two most advanced hematological cancer programs TSC-100 and TSC-101 and nominate a third, undisclosed program in the second half of this year.

Southwell said the companys lead programs are for the hematological cancers acute myeloid leukemia, myelodysplastic syndrome, and T-cell acute lymphoblastic leukemia.

TSC-100, currently in IND-enabling studies, targets minor histocompatibility antigen HA-1 that is highly expressed in leukemia but much less so in normal tissue. TSC-101 targets a similar antigen, HA-2, and is preclinical studies. Lead candidate TSC-100 is being developed as a therapy for leukemia patients following hematopoietic stem cell transplant treatment, the current standard of care. As many as 40% of patients relapse following transplant, but some patients with lower relapse rates develop T cells targeting tumor antigens like HA-1 and HA-2.

TScan aims to have five programs in the clinic by the end of 2022, said Southwell.

Recently, we have identified over 40 novel cancer targets from clinically active TCRs for development of multiplexed TCR-T cell therapies as part of our solid tumor program, Southwell said. Our goal is to continue to build a bank of clinically-active TCRs throughout 2021.

BlackRock and RA Capital joined TScans founding investor, Longwood Fund, and existing investors 6 Dimensions Capital, Bessemer Venture Partners, GV, Novartis Venture Fund and Pitango HealthTech. TScans previous venture rounds include a split Series B that raised $35 million in January 2020 and $45 million in July 2019.

TScan also partnered with Novartis last year to discover and develop TCR-engineered T cell therapies for up to three solid tumor targets, a deal worth $30 million up front. Under the terms of the deal, TScan will use its platform to identify novel cancer antigens and TCRs that can target them. Novartis can then license and develop therapies.

TScans platform is based on the work of scientific cofounders Stephen Elledge and Tomasz Kula, who developed a systematic process to determine which peptide antigens are discovered by cytotoxic T cells, the primary human immune tool for eliminating cancer. Elledge is a professor of genetics at Harvard Medical School and Brigham and Womens Hospital, and Kula is a junior fellow at Harvard University.

The company is also using the platform to seek therapeutic targets in infectious and autoimmune diseases, and last year TScan announced partnerships with Poseida Therapeutics and Qiagen to develop a T cell therapy and rapid diagnostic, respectively, for SARS-CoV-2.

Most Read Today

More here:
TScan Moves Toward the Clinic with $100 Million Series C Round - BioSpace

Love Your Skin: What Is SPF And Why Is It Important? – Yahoo Movies Canada

The Daily Beast

Gabe Ginsberg/GettyOne of Saturday Night Lives most notorious former stars has turned his radio show into a regular platform for his business partner, cushion and conspiracy hawker Mike Lindell, amplifying the Trump-loving MyPillow founder and his unfounded claims about the election, Twitter censorship, and the deadly Capitol insurrectionist riot.Between the early 1980s and the early 2010s, Joe Piscopo went from SNL fan favorite to punchlinebut resurrected his career in 2014 with Piscopo in the Morning, a four-hour block on AM 970, a talk-radio station popular with New York City commuters. Since the election of now-former President Donald Trump, Piscopos guests have often been a mix of dubious conservative commentators and more mainstream figures like former NYPD Commissioner Ray Kelly. By 2018, his show had climbed into the top 50 most-streamed and most influential radio programs in the country, according to an industry poll.In 2021, and particularly after Trump supporters rioted at the Capitol on Jan. 6, Piscopo has repeatedly given airtime in the largest U.S. media market to Lindell, even though such hard-right outlets like Newsmax had by then sought to block the MyPillow magnate from making his outrageous claims on their air.Undisclosed in these recurring appearances is that Piscopo and Lindell have been business partners for several years. In 2017, the duo launched a supplement line called Nutrajoe, for which Lindell filed and obtained the trademarks. The product was marketed via infomercial, much like MyPillow, and promoted on Lindells corporate Twitter account. The company remains an active concern, according to Minnesota corporate filings, though its website appears defunct.MyPillow CEO Mike Lindell Is Throwing Down Big Money to Fuel Pro-Trump Election ChallengesRepresentatives for Piscopo and Lindell did not respond to requests for comment about the latters appearances on the formers show, nor about their ongoing business relationship.The antifa that I believe was already there, they started early on that, and actually I have videos of Trump supporters trying to hold back the guy who was breaking the first window, Lindell said on Piscopos show on Jan. 7, when he was brought on as a reliable eyewitness to testify to the supposed involvement of leftist protesters in the moba notion federal investigators have discounted. It was started by antifa. Antifa did it.Not only did Piscopo not challenge Lindells claims, but he lauded him as a great patriot and echoed his assertions that the right-wing extremists dressed in paramilitary gear were in fact undercover left-wing agitators.Lindell then pivoted into his favorite topic: the fantasy that an elaborate international conspiracy rigged the November election for President Joe Biden, allegations that court after court threw out in the weeks following the vote.You got 80 million people Joe, that know this election, or 100 million people that know this election was stolen from them, Lindell said. I know it personally, Ive seen the evidence.The MyPillow CEO went on to assert without any proof that dead people and minors had provided Bidens margin of victory in an unspecified state.Its like a bad SNL sketch, man, Piscopo exclaimed, a remark apparently intended as approving.Baseless allegations of election fraud were a theme Lindell returned to in a subsequent appearance on the show on Jan. 21days after he went to the White House to present a proposal to the lame-duck Trump for imposing martial law. The pillow mogul reiterated his claims that foreign actors and voting machine manufacturer Dominion manipulated the vote totals, an assertion which has led to threats of legal action from the latter.Im not backing down, Im going to keep going until these machines are exposed, Lindell said, interspersing his speculations with allegations that Dominion pressured multiple retailers into dumping his product. This is so massive, you will never ever be able to have elections with machines. Eighty-five percent of them were online, they went over to five different countries. We actually have the forensic footprint thats inside now.My number-one purpose on this planet is to get these machines so we never use them again, and we get this fraud, fraudulent election exposed, and these countries attacked us, Lindell said, near the conclusion of his 15-minute-long rant.MyPillow Guy Presents Trump With China Election-Fraud Theory, Lawyers Send Him PackingThe Trump White Houses own lawyers rejected Lindells notions less than a week prior, but Piscopo backed Lindell up.These machines, they really seemhow, how did we end up with these machines? Why are we using these machines? the host wondered. Thanks for your patriotism, thanks for your faith, thanks for being the great person you are, Mike Lindell.The conversation only turned more paranoid when Lindell returned the morning of Jan. 26, a day after Twitter permanently banned him from its platform. There, the unhinged pillow manufacturer offered a preview of the strange claims hed make on Tucker Carlsons show that night: namely, that Twitter CEO Jack Dorsey had taken control of Lindells account in the days previous to the ban. Mike Lindell, Inventor and CEO of @MyPillowUSA, joined @JrzyJoePiscopo to discuss him being permanently banned from Twitter Full Interview: https://t.co/dyEM6G7ZKw pic.twitter.com/Ez9DN813Cq The Joe Piscopo Show (@JoePiscopoShow) January 26, 2021 Twitter was running my Twitter account and acting like they were Mike Lindell, Lindell claimed. These guys were putting up posts that my friends knew I would not put up. That was Jack Dorsey doing this stuff behind the scenes trying to destroy me.Unlike Carlson, who that night struck an agnostic attitude and declined to endorse or deny his guests insane claims, Piscopo offered his sympathieswhich he bizarrely coupled with a product promotion.Oh my gosh, you know what Mike, thank you, because I called you, Piscopo said in response. I cannot believe they did this, and Im telling everybody to go out and get as many MyPillows as they possibly can.Lindell then pivoted to the subject of his 100-percent evidence of machine fraud, to which Piscopo joined in expressions of amazement and support.We have affidavits, you see video, and now youre telling us that mathematically the numbers were in fact stolen or just plain not recorded, Piscopo said, citing supposed proof that was retracted or rejected in multiple courts.Read more at The Daily Beast.Got a tip? Send it to The Daily Beast hereGet our top stories in your inbox every day. Sign up now!Daily Beast Membership: Beast Inside goes deeper on the stories that matter to you. Learn more.

See the article here:
Love Your Skin: What Is SPF And Why Is It Important? - Yahoo Movies Canada

Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction – Cath Lab…

Initiation of the Phase 2b FREEDOM trial represents the next step in development of CLBS16 as a potential breakthrough treatment for the millions of sufferers of CMD in the U.S., most of whom are women

Patient enrollment underway atTheChrist Hospital Health Network in Cincinnati (OH) and Mayo Clinic in Rochester (MN) with additional sites across the United States targeted to open soon

Strong investigator and subject interest driven by the positive results of the Phase 2a ESCaPE-CMD trial reported in spring of 2020

BASKING RIDGE, N.J. (January 29, 2021) Caladrius Biosciences, Inc.,a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, announced that it has treated the first patient in its Phase 2b FREEDOM trial of CLBS16 as a therapy for coronary microvascular dysfunction (CMD) at TheChrist Hospital Health Network in Cincinnati, Ohio. The 105-patient double-blind and placebo-controlled clinical trial is designed to further evaluate the efficacy and safety of intracoronary delivery of autologous CD34+ cells (CLBS16) in subjects with CMD and without obstructive coronary artery disease.

We are very excited about our CLBS16 program as it represents a potential breakthrough in the treatment of CMD, a condition which afflicts millions of patients in the US alone, many of whom are women. As a result, CMD is a womens health issue of emerging importance as currently there are no products with approved labeling for coronary microvascular dysfunction, said David J. Mazzo, PhD, President and Chief Executive Officer of Caladrius. The treatment of the first patient in the FREEDOM trial is an important milestone for our Company and the program and we look forward to completing enrollment by the target of year-end 2021. It is especially noteworthy that even during the COVID-19 pandemic, physicians and patients are active in our trial, denoting the seriousness of the disease and underscoring the lack of available effective treatment for CMD.

Following the outstanding full data results from the ESCaPE-CMD study that I presented at SCAI 2020, we are very excited to participate in the FREEDOM trial, said Timothy D. Henry, M.D., Medical Director of the Carl and Edyth Lindner Center for Research at TheChrist Hospital Health Network. Caladrius CLBS16 program has demonstrated great promise and I am looking forward to seeing how this new therapeutic option can benefit patients with CMD.

For more information on this study, please visitclinicaltrials.gov(identifier: NCT04614467).

If you are a patient or a physician and have questions about eligibility for this study, please visitwww.freedom-trial.com.

About Coronary Microvascular Dysfunction

Coronary microvascular dysfunction is a type of non-obstructive coronary artery disease that causes decreased blood flow to the heart muscle that affects approximately 8.3 million people in the U.S.1,2With common symptoms that include recurring, debilitating chest pain, tiredness, and shortness of breath, many CMD patients are undiagnosed because of the absence of large vessel obstruction. Due to an under appreciation of the disease, patients, the majority of whom are women, often go years without proper treatment. When a diagnosis of CMD is missed, patients are untreated and remain at high risk of heart attack and/or cardiovascular-related death. _______________________ [1] Mittal, S.R.; Indian Heart Journal, Volume 66, 2014, Pages 678681 [2] Cleveland Clinic/AHA (American Heart Association)

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.

The Companys current product candidates include: HONEDRA (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (CLI) based on the results of an ongoing clinical trial; OLOGO (formerly CLBS14), a Regenerative Medicine Advanced Therapy (RMAT) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the FDA) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (NORDA); CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction (CMD); CLBS119, an emergent CD34+ stem cell therapy responding to the COVID-19 pandemic and the potentially permanent damage the virus inflicts on the lungs of many patients; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for chronic kidney disease (CKD). For more information on the company, please visitwww.caladrius.com.

Read more:
Caladrius Biosciences Treats First Patient in the Phase 2b FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction - Cath Lab...

From hacking the immune system at the Parker Institute to decoding and reprogramming human cells – leading clinical immunotherapies developer Ramy Ibr…

Disclaimer: You are now leaving PharmiWeb.com website and are going to a website that is not operated by us. We are not responsible for the content or availability of linked sites.

ABOUT THIRD PARTY LINKS ON OUR SITE

PharmiWeb.com offers links to other third party websites that may be of interest to our website visitors. The links provided in our website are provided solely for your convenience and may assist you in locating other useful information on the Internet. When you click on these links you will leave the PharmiWeb.com website and will be redirected to another site. These sites are not under the control of PharmiWeb.com.

PharmiWeb.com is not responsible for the content of linked third party websites. We are not an agent for these third parties nor do we endorse or guarantee their products. We make no representation or warranty regarding the accuracy of the information contained in the linked sites. We suggest that you always verify the information obtained from linked websites before acting upon this information.

Also, please be aware that the security and privacy policies on these sites may be different than PharmiWeb.com policies, so please read third party privacy and security policies closely.

If you have any questions or concerns about the products and services offered on linked third party websites, please contact the third party directly.

Read more from the original source:
From hacking the immune system at the Parker Institute to decoding and reprogramming human cells - leading clinical immunotherapies developer Ramy Ibr...

City Awards $38 Million in Infrastructure Grants for City Science Institutions – CityLand CityLand – CityLand

Part of the Albert Einstein College of Medicine in the Bronx, one of the four recipients of grants from the city. Image Credit: Google Maps

Four New York City leading scientific research facilities are receiving infrastructure grants to advance innovation and public health. On January 21, 2021, Mayor de Blasio announced that Columbia University, Montefiore-Einstein, the New York Stem Cell Foundation, and Rockefeller University are the four winners of $38 million in infrastructure grants for research and development departments. These grants come as a part of LifeSci NYC, a $500 million project with the goal of establishing New York City as a public health capital.

Each of the four facilities is dedicated to forming partnerships between New Yorks leading scientists and technological and pharmaceutical companies around the world. Columbia Universitys Therapeutic Validation Center is using its $9 million grant to accelerate early research into new start-ups. The center will be using new technology to create new medicines to eliminate diseases. The center will be located within Columbia Universitys facilities. Dr. Brent Stockwell, a professor of biological sciences and chemistry at Columbia University stated, We anticipate that the Center will launch multiple life science companies in NYC that create transformational medicines to change the landscape of treatment for COVID-19 and other human maladies.

Montefiore Medicine is using its $13 million grant to launch the Einstein-Montefiore Biotechnology Accelerated Research Center. The center will focus on cell, gene, and antibody therapy production and will be located on Montefiores Einstein campus in Morris Park. The center is to be open to early stage and established companies in need of these kinds of facilities.

New York Stem Cell Foundation will use its $6.5 million to expand its research institute located in West Midtown. The expansion will allow the facility to turn their research directly into clinic-ready drugs and treatments. The new equipment will increase the facilities production, processing, and screening capabilities. The expansion will also allow for collaborations with universities, technology companies, and pharmaceutical companies. Susan L. Solomon, founder, and CEO of the New York Stem Cell Foundation, stated, Developing drugs and new treatments on human cells is critical and I am very excited that the City continues to make this a priority.

The Rockefeller University is using its $9 million grant to convert research labs into the Tri-Institutional Translational Center for Therapeutics which will work with commercial life sciences. The facility will be working with Memorial Sloan Kettering Cancer Center and Weil Cornell Medicine to better their growth. The facility will be located in Upper East Side. President of Rockefeller University, Richard P. Lifton stated, By consolidating existing collaborations and providing much-needed biotech incubator space into the bargain, this new center will focus the boldest biomedical science in the world on solving todays most challenging medical problems while also growing the fast-emerging biotech sector in New York City.

Mayor de Blasio stated, As we rebuild a fairer and better city, its time to make New York City a global leader in pandemic response. This city will stand with the life sciences in good times and bad, and I cant wait to see what our world-class partners will create in the years to come.

This announcement coincides with the creation of the Pandemic Response Institute, a hub for preparing for future emergencies, and the Pandemic Response Lab, which processes COVID-19 tests for NYC Health and Hospitals.

By: Patrick McNeill(Patrick is a CityLaw intern and a New York Law School student, Class of 2022.)

Follow this link:
City Awards $38 Million in Infrastructure Grants for City Science Institutions - CityLand CityLand - CityLand